Nevro Corp. (NYSE:NVRO) today closed its initial public offering, saying it raised $144.9 million by offering 8.05 million shares at $18 apiece.
Funding Roundup
Lantheus resuscitates IPO
Lantheus Medical Imaging revived plans for an initial public offering last week, but didn’t set any terms for the flotation.
It’s the 2nd run at the public markets for Billerica, Mass.-based Lantheus, which makes medical imaging isotopes.
Biolase lands $35m private placement
Vascular Dynamics raises $10m
Vascular Dynamics said it raised nearly $10 million from a group of unnamed investors for the hypertension implant it’s developing.
The Mountain View, Calif.-based startup reported raising $9.7 million in an offering of stock, warrants and other securities as part of a proposed $22.9 million funding round.
Second Sight eyes $32m IPO
Second Sight Medical said today that it plans to raise $31.5 million in an initial public offering, likely next week.
Second Sight created the Argus II "bionic eye," the 1st retinal prosthesis approved for sale by the FDA.
Nevro boosts IPO to $126m
Nevro Corp. today raised the stakes on its forthcoming initial public offering, saying it will offer half a million more shares at a dollar over the high end of its prior range.
InspireMD seeks to raise $8m in direct offering
Sientra nets $80m in IPO
Sientra prices $75m IPO
Breast implant maker Sientra priced its initial public offering at $15 per share, saying it plans to issue 5 million shares for a total of $75 million.
Sientra, which also has designed implants for the buttocks, calf, pectoral region and face, has backers including Abingworth Bioventures, OrbiMed and Clarus Lifesciences.
Nevro sets range for IPO of up to $106m
Nevro Corp. set the price range for its forthcoming initial public offering, which would raise $106.3 million at the high end of the range.
Menlo Park, Calif.-based Nevro plans to trade on the NASDAQ exchange under the symbol NVRO, according to a regulatory filing.